-
Far-right Kast wins Chile election in landslide
-
What we know about Australia's Bondi Beach attack
-
Witnesses tell of courage, panic in wake of Bondi Beach shootings
-
Chiefs out of playoffs after decade as Mahomes hurts knee
-
Chilean hard right victory stirs memories of dictatorship
-
Volunteers patrol Thai villages as artillery rains at Cambodia border
-
Far-right candidate Kast wins Chile presidential election
-
Father and son gunmen kill 15 at Jewish festival on Australia's Bondi Beach
-
Rodrygo scrapes Real Madrid win at Alaves
-
Jimmy Lai, the Hong Kong media 'troublemaker' in Beijing's crosshairs
-
Hong Kong court to deliver verdicts on media mogul Jimmy Lai
-
Bills rein in Patriots as Chiefs eliminated
-
Chiefs eliminated from NFL playoff hunt after dominant decade
-
Far right eyes comeback as Chile presidential polls close
-
Freed Belarus dissident Bialiatski vows to keep resisting regime from exile
-
Americans Novak and Coughlin win PGA-LPGA pairs event
-
Zelensky, US envoys to push on with Ukraine talks in Berlin on Monday
-
Toulon edge out Bath as Saints, Bears and Quins run riot
-
Inter Milan go top in Italy as champions Napoli stumble
-
ECOWAS threatens 'targeted sanctions' over Guinea Bissau coup
-
World leaders express horror at Bondi beach shooting
-
Joyous Sunderland celebrate Newcastle scalp
-
Guardiola hails Man City's 'big statement' in win at Palace
-
Lens reclaim top spot in Ligue 1 with Nice win
-
No 'quick fix' at Spurs, says angry Frank
-
Toulon edge to victory over Bath, Saints and Quins run riot
-
Freed Belarus protest leader Kolesnikova doesn't 'regret anything'
-
Man City smash Palace to fire title warning, Villa extend streak
-
Arshdeep helps India beat South Africa to take T20 series lead
-
Zelensky meets US envoys in Berlin for talks on ending Ukraine war
-
'Outstanding' Haaland stars in win over Palace to fire Man City title charge
-
Man City smash Palace to fire title warning, Villa extend winning run
-
Napoli stumble at Udinese to leave AC Milan top in Serie A
-
No contact with Iran Nobel winner since arrest: supporters
-
Haaland stars in win over Palace to fire Man City title charge
-
French PM urged to intervene over cow slaughter protests
-
'Golden moment' as Messi meets Tendulkar, Chhetri on India tour
-
World leaders express horror, revulsion at Bondi beach shooting
-
Far right eyes comeback as Chile presidential vote begins
-
Marcus Smith shines as Quins thrash Bayonne
-
Devastation at Sydney's Bondi beach after deadly shooting
-
AC Milan held by Sassuolo in Serie A
-
Person of interest in custody after deadly shooting at US university
-
Van Dijk wants 'leader' Salah to stay at Liverpool
-
Zelensky in Berlin for high-stakes talks with US envoys, Europeans
-
Norway's Haugan powers to Val d'Isere slalom win
-
Hong Kong's oldest pro-democracy party announces dissolution
-
Gunmen kill 11 at Jewish festival on Australia's Bondi Beach
-
Zelensky says will seek US support to freeze front line at Berlin talks
-
Man who ploughed car into Liverpool football parade to be sentenced
Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
O.Lorenz--BTB